Insurance coverage for genomic tests

Kathryn A Phillips^{1

2

3}, Julia R Trosman⁴, Patricia A Deverka^{5

6}, Bruce Quinn⁷, Sean Tunis⁸, Peter J Neumann⁹, James D Chambers⁹, Louis P Garrison Jr¹⁰, Michael P Douglas⁵, Christine B Weldon⁴

Affiliations

¹ Department of Clinical Pharmacy, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California San Francisco, San Francisco CA 94143, USA. kathryn.phillips@ucsf.edu.
² Philip R. Lee Institute for Health Policy, San Francisco, CA 94118, USA.
³ Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA.
⁴ Center for Business Models in Healthcare, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
⁵ Department of Clinical Pharmacy, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California San Francisco, San Francisco CA 94143, USA.
⁶ American Institutes for Research, Chapel Hill, NC 27517, USA.
⁷ Bruce Quinn Associates, Los Angeles, CA 90036, USA.
⁸ Center for Medical Technology Policy (CMTP), Baltimore, MD 21202, USA.
⁹ The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA.
¹⁰ The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy, University of Washington, Seattle, WA 98195, USA.

Kathryn A Phillips et al. Science. 2018.

. 2018 Apr 20;360(6386):278-279.

doi: 10.1126/science.aas9268. Epub 2018 Apr 19.

¹ Department of Clinical Pharmacy, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California San Francisco, San Francisco CA 94143, USA. kathryn.phillips@ucsf.edu.
² Philip R. Lee Institute for Health Policy, San Francisco, CA 94118, USA.
³ Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA.
⁴ Center for Business Models in Healthcare, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
⁵ Department of Clinical Pharmacy, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California San Francisco, San Francisco CA 94143, USA.
⁶ American Institutes for Research, Chapel Hill, NC 27517, USA.
⁷ Bruce Quinn Associates, Los Angeles, CA 90036, USA.
⁸ Center for Medical Technology Policy (CMTP), Baltimore, MD 21202, USA.
⁹ The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA.
¹⁰ The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy, University of Washington, Seattle, WA 98195, USA.

No abstract available

References

1. CMS. Decision Memo for Next-Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450N) 2018 www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NC....
1. Eisenberg R, Varmus H. Science. 2017;358:1133. - PubMed
1. Phillips KA, et al. Nat Biotechnol. 2017;35:614. - PMC - PubMed
1. Chambers JD, Chenoweth M, Thorat T, Neumann PJ. Health Aff (Millwood) 2015;34:1376. - PubMed
1. Levinson DR. Local coverage determinations create inconsistency in Medicare coverage. 2014 https://oig.hhs.gov/oei/reports/oei-01-11-00500.pdf.